Myelodysplastic Syndromes

>

Latest News

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS

March 14th 2024

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.

Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.
Rusfertide May Help Control Erythrocytosis in Polycythemia Vera

March 8th 2024

Treatment with imetelstat produces robust activity in patients with relapsed/refractory myelodysplastic syndrome regardless of ring sideroblasts in the phase 3 IMerge trial.
Imetelstat Yields Enduring RBC-TI in Lower-Risk Relapsed/Refractory MDS

January 16th 2024

Pelabresib/Ruxolitinib Improves SVR35/TSS Outcomes in Myelofibrosis
Pelabresib/Ruxolitinib Improves SVR35/TSS Outcomes in Myelofibrosis

December 12th 2023

Video Interviews

More News